Affiliation:
1. Division of Pulmonary and Sleep Medicine, Department of Pediatrics University of Alabama at Birmingham Birmingham Alabama USA
2. Gregory Fleming James Cystic Fibrosis Research Center University of Alabama at Birmingham Birmingham Alabama USA
3. Lister Hill Library of Health Science University of Alabama at Birmingham Birmingham Alabama USA
4. Department of Pediatrics University of Arkansas for Medical Sciences Little Rock Arkansas USA
Abstract
AbstractNewborn screening for cystic fibrosis (CF) occasionally results in an inconclusive diagnosis of this disease, and these individuals are designated as CFTR‐related metabolic syndrome (CRMS) in the United States, and CF Screen Positive Inconclusive Diagnosis (CFSPID) in other countries. Some of these asymptomatic individuals will progress to symptomatic disease, but risk factors associated with disease progression are not well understood. This scoping review was conducted to comprehensively map nonbiological risk factors in the CRMS/CFSPID literature and to identify understudied topics. Six electronic databases were systematically searched, resulting in 2951 studies. Forty nine eligible works were identified as including information on nonbiological risk factors related to CRMS/CFPSID. Eligible studies were published from 2002 to 2024, most prevalently in the United States (36.7%), and as quantitative data (81.6%). Of the 49 eligible works, 23 articles contributed only intellectual conjecture, while 26 articles contained original data, which underwent full‐text qualitative content analysis. Key themes identified in descending order of content coverage included Psychological Impact, Management Care, Newborn Screening and Diagnostics, Communicating Diagnosis, and Lifestyle and External Exposures. This scoping review identified that while nonbiological risk factors are being studied in the CRMS/CFSPID literature, there was nearly equal distribution of works gathering original data to those citing previously published information. These findings indicate a critical need for original data collection on these risk factors, particularly on understudied topics identified herein.
Funder
Cystic Fibrosis Foundation
National Institute of Diabetes and Digestive and Kidney Diseases
National Heart, Lung, and Blood Institute
Reference91 articles.
1. About Cystic Fibrosis | Cystic Fibrosis Foundation. Published 2024. Accessed February 21 2024.https://www.cff.org/intro‐cf/about‐cystic‐fibrosis
2. People With CF Are Living Longer. What Does That Mean for Our Care? | Cystic Fibrosis Foundation. Published August 11 2022. Accessed February 21 2024.https://www.cff.org/community‐posts/2022‐08/people‐cf‐are‐living‐longer‐what‐does‐mean‐our‐care
3. Newborn screening for cystic fibrosis
4. Updated guidance on the management of children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID)
5. Newborn screening for cystic fibrosis;Southern KW;Cochrane Database Syst Rev,2009